This advanced anti-PD-L1 TMZ-TK NP system exhibited potent antitumor activity, including DNA damage and inhibition of angiogenic markers, offering a versatile and broadly applicable approach to cancer therapy (Fig. S1C). The gene discussed is CD274; the disease is cancer.